FR2970179B1 - Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques - Google Patents

Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques

Info

Publication number
FR2970179B1
FR2970179B1 FR1150208A FR1150208A FR2970179B1 FR 2970179 B1 FR2970179 B1 FR 2970179B1 FR 1150208 A FR1150208 A FR 1150208A FR 1150208 A FR1150208 A FR 1150208A FR 2970179 B1 FR2970179 B1 FR 2970179B1
Authority
FR
France
Prior art keywords
metastasic
eradicating
cancer
reducing
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1150208A
Other languages
English (en)
Other versions
FR2970179A1 (fr
Inventor
Cedric Darini
Christian Dani
Milou Daniel Drici
Annie Ladoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Nice Sophia Antipolis UNSA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1150208A priority Critical patent/FR2970179B1/fr
Priority to PCT/IB2012/050144 priority patent/WO2012095804A1/fr
Publication of FR2970179A1 publication Critical patent/FR2970179A1/fr
Application granted granted Critical
Publication of FR2970179B1 publication Critical patent/FR2970179B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1150208A 2011-01-11 2011-01-11 Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques Expired - Fee Related FR2970179B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1150208A FR2970179B1 (fr) 2011-01-11 2011-01-11 Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques
PCT/IB2012/050144 WO2012095804A1 (fr) 2011-01-11 2012-01-11 Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1150208A FR2970179B1 (fr) 2011-01-11 2011-01-11 Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques

Publications (2)

Publication Number Publication Date
FR2970179A1 FR2970179A1 (fr) 2012-07-13
FR2970179B1 true FR2970179B1 (fr) 2013-01-18

Family

ID=44454838

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1150208A Expired - Fee Related FR2970179B1 (fr) 2011-01-11 2011-01-11 Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques

Country Status (2)

Country Link
FR (1) FR2970179B1 (fr)
WO (1) WO2012095804A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033654A1 (fr) * 1998-12-04 2000-06-15 University Of Maryland Biotechnology Institute Utilisation d'inhibiteurs de protease pour moduler les chemins cellulaires, immunite et therapies associees
AU2003256847A1 (en) * 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
US7812034B2 (en) * 2003-11-04 2010-10-12 City Of Hope Method of using protease inhibitors for the treatment of liposarcomas
WO2009126310A2 (fr) * 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Procédés d’identification et utilisation d’agents ciblant les cellules souches cancéreuses

Also Published As

Publication number Publication date
WO2012095804A1 (fr) 2012-07-19
FR2970179A1 (fr) 2012-07-13

Similar Documents

Publication Publication Date Title
LTC2649086I2 (lt) Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
HK1251012A1 (zh) 使用胎盤幹細胞對骨相關癌的治療
DK2694640T3 (da) Reversion af effekterne af tumormikromiljø ved anvendelse af kimæriske cytokinreceptorer
EP2904106A4 (fr) Compositions et procédés de ciblage de cellules stromales pour le traitement du cancer
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
EP2710137A4 (fr) Combinaison de thérapies immunomodulatrices locales et systémiques pour l'amélioration du traitement du cancer
BR112014001440A2 (pt) novas composições e métodos para o tratamento de câncer de próstata
HUE050622T2 (hu) Rák õssejteket érintõ rák diagnosztizálása és kezelése
DK2547205T3 (da) Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
HRP20181212T1 (hr) Anti-alfa-v integrinsko protutijelo za liječenje raka prostate
EP2768499A4 (fr) Analogues de l'indométacine destinés au traitement du cancer de la prostate résistant à la castration
PT2831110T (pt) Terapia anti-emp2 reduz as células-tronco do cancro
FR2970179B1 (fr) Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques
EP2756092A4 (fr) Procédés de fabrication de cellules, de tissus et d'anticorps
GB201112637D0 (en) The process of nanostenting and nanomeshing cancer cells
AU2011900981A0 (en) Inhibition of cancer stem cells

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140930